Authors: D. Belada 1; K. Polgárová 2 Authors‘ workplace: IV. interní hematologická klinika LF UK a FN Hradec Králové 1; I. interní klinika VFN v Praze 2 Published in: Transfuze Hematol. dnes,31, 2025, No. 4, p. 269-277. Category: Review/Educational Papers doi: https://doi.org/10.48095/cctahd202522
Diffuse large B-cell lymphoma (DLBCL) represents a heterogeneous group of diseases within the category of non-Hodgkin lymphomas, generally associated with a relatively good prognosis. First-line treatment cures approximately 60% of patients. About 40% of patients, however, experience relapse or have primary refractory disease. The prognosis for these patients was historically very poor. In the treatment of relapsed/refractory DLBCL, the timing of first-line treatment failure is currently a key factor. If the failure occurs within 12 months after completion of first-line therapy and the patient is eligible for CAR-T therapy, axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel) should be administered. If the relapse occurs after more than 12 months and the patient is suitable for high-dose therapy, salvage immunochemotherapy followed by autologous stem cell transplantation is indicated. If the patient is not eligible for such high-dose therapy, immunochemotherapy remains the standard second-line treatment. In third and later lines of therapy, more treatment options are now available. These include the bispecific antibody glofitamab. If the patient has not previously received CAR-T therapy, CAR-T treatment is also an option. In cases where these treatment modalities fail, loncastuximab tesirine is available in the Czech Republic for third and later lines of therapy. Other treatment options include the bispecific antibody epcoritamab, the combination of tafasitamab + lenalidomide, or the Pola-BR regimen. However, these treatments are not currently reimbursed, and approval must be requested from the relevant health insurance company under Paragraph 16. A very promising approach is the combination of glofitamab with the GEMOX regimen for second and later lines, based on data from the STARGLO clinical trial. However, this treatment is also not yet reimbursed in the Czech Republic. Looking ahead, it is expected that these new treatment modalities will shift into earlier lines of therapy, but results from ongoing clinical trials must be awaited. Nonetheless, it can be stated that the prognosis for patients with relapsed/refractory DLBCL has significantly improved in recent years.
lymphoma – Prognosis – relapse – DLBCL – CAR-T – axi-cel – liso-cel – bispecific antibodies – glofitamab
1. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med. 2002; 346 (4): 235–242. doi: 10.1056/NEJMoa011795.
2. Tilly H, Gutiérrez-García G, Sehn LH, et al. Polatuzumab vedotin for diffuse large B cell lymphoma. N Engl J Med. 2022; 387 (8): 351–363. doi: 10.1056/NEJMoa2115304.
3. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B cell lymphoma: results from the international SCHOLAR 1 study. Blood. 2017; 130 (16): 1800–1808. doi: 10.1182/blood 2017 03 769620.
4. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380 (1): 45–56. doi: 10.1056/NEJMoa180 4980.
5. Neelapu SS, Jacobson CA, Oluwole OO, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020; 135 (23): 2106–2109. doi: 10.1182/blood.2019004162.
6. Locke FL, Neelapu SS, Bartlett NL, et al. Axicabtagene ciloleucel as therapy for relapsed or refractory large B cell lymphoma. N Engl J Med. 2017; 377 (26): 2531–2544. doi: 10.1056/ NEJMoa1707447.
7. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet. 2020; 396 (10254): 839–852. doi: 10.1016/S0140 6736 (20) 31366 0.
8. Locke FL, Miklos DB, Jacobson C-A, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma (ZUMA-7): overall survival analysis of a randomised, phase 3 trial. N Engl J Med. 2022; 386 (7): 640–654. doi: 10.1056/NEJMoa2116133.
9. Caimi PF, Nastoupil LJ, Wang M, et al. Real-world outcomes of axicabtagene ciloleucel (axi-cel) for relapsed or refractory large B-cell lymphoma: results from a US multicenter registry. Blood Adv. 2022; 6 (16): 4845–4854. doi: 10.1182/bloodadvances.2022008018.
10. Kamdar M, Morschhauser F, Schuster SJ, et al. Three-year outcomes from the TRANSFORM study of lisocabtagene maraleucel vs standard of care in second-line relapsed or refractory large B-cell lymphoma. J Clin Oncol. 2024; 42 (16_suppl): 7013. doi: 10.1200/JCO.2024. 42.16_suppl.7013.
11. Cazelles C, Belhadj K, Vellemans H, et al. Real-world (RW) outcomes of lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) and secondary central nervous system (sCNS) involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 2024; 144 (Suppl 1): 472. doi: 10.1182/blood-2024-194887.
12. Cazelles C, Belhadj K, Vellemans H, et al. Rituximab plus gemcitabine and oxaliplatin (R GemOx) in refractory/relapsed (R/R) diffuse large B cell lymphoma: A real life study in patients ineligible for autologous stem cell transplantation. Hematol Oncol. 2019; 37 (S2): 429.
13. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2020; 382 (6): 599–609. doi: 10.1056/NEJM oa1908390.
14. Iacoboni G, Stathis A, Morschhauser F, et al. Effect of bendamustine exposure prior to apheresis on outcomes in large B-cell lymphoma treated with CD19 CAR T-cell therapy. J Clin Oncol. 2023; 41 (28): 4805–4814.
15. Cheson BD, Gabrilove J, Radford J, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022; 387 (24): 2285–2296.
16. Weber I, Blaeschke F, Henssen AG, et al. Safety and efficacy of glofitamab for relapsed or refractory large B-cell lymphoma in routine clinical practice. Blood Adv. 2024; 8 (2): 379–391. doi: 10.1182/bloodadvances.2024014903.
17. Thieblemont C, Morschhauser F, Palomba ML, et al. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. J Clin Oncol. 2023; 41 (16_suppl): 7525. doi: 10.1200/JCO.2023. 41.16_suppl.7525.
18. Morschhauser F, Thieblemont C, Dickinson M, et al. Odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed or refractory diffuse large B-cell lymphoma (ELM-2): results from a multicentre, open-label, phase 2 study. Lancet Haematol. 2024; 11 (6): e398–e410. doi: 10.1016/S2352-3026 (24) 00056-2.
19. Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20×CD3 bispecific antibody, induces durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: results from a first-in-human study (ELM-1). J Clin Oncol. 2022; 40 (4): 367–376. doi: 10.1200/JCO.21.01805.
20. Caimi PF, Palomba ML, Morschhauser F, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021; 22 (6): 790–800. doi: 10.1016/S1470-2045 (21) 00127-0.
21. Duell J, Abrisqueta P, Andre M, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2020; 21 (7): 978–988. doi: 10.1016/S1470-2045 (20) 30347-1.
22. Saverno K, Nastoupil L, Feinberg B, et al. Real-world effectiveness of tafasitamab (Tafa) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in the United States. Blood. 2024; 144 (Suppl 1): 2375. doi: 10.1182/blood-2024-193264.
23. Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024; 404 (10466): 1940–1954. doi: 10.1016/S0140-6736 (24) 01774-4.
24. Hutchings M, Mous R, Federico M, et al. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 1b/2 EPCORE NHL-2 trial. Blood. 2024; 145 (15): 1621–1630. doi: 10.1182/blood.2024026830.
25. Shadman M, Armand P, Dai T, et al. Allogeneic hematopoietic cell transplantation for relapsed or refractory diffuse large B-cell lymphoma in the era of CAR T-cell therapy. Blood Adv. 2021; 5 (15): 2900–2911. doi: 10.1182/bloodadvances.2021004388.
26. Thomson KJ, Morris EC, Milligan D, et al. Allogeneic hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: relapse risk, long-term outcomes and the graft-versus-lymphoma effect. Haematologica. 2013; 98 (5): 759–766. doi: 10.3324/ haematol.2012.070300.
27. Kittai AS, Lee HJ, Glover J, et al. Comparison of CAR T-cell therapy versus bispecific antibody therapy in relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis. Blood. 2024; 144 (6): 629–639. doi: 10.1182/blood.2023012345.
28. Shah NN, Lee Y, Gutierrez C, et al. Indirect treatment comparison of epcoritamab versus axicabtagene ciloleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2024; 8 (4): 1010–1020. doi: 10.1182/bloodadvances. 2023008765.
PODÍL AUTORŮ NA ZPRACOVÁNÍ ČLÁNKU
David Belada – tvorba publikace
Kamila Polgárová – revize textu
PROHLÁŠENÍ O STŘETU ZÁJMŮ
DB – poradenská činnost, přednášková činnost a podpora výzkumu od firem: Gilead Sciences, Roche, Abbvie, Takeda, BMS, Swixx, Janssen Cilag
KP – poradenská činnost, přednášková činnost a podpora výzkumu od firem: Gilead Sciences, Roche, Abbvie, Takeda, BMS, Swixx
PODÍL AI (UMĚLÉ INTELIGENCE)
jazyková korekce abstraktu v anglickém jazyce
PODĚKOVÁNÍ
Tato práce byla podpořena projektem PROGRES Q40/08, COOPERATIO (vědní oblast INDI)
a grantem NU21-03-00411.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
